Lung Cancer 2022 is part of the Tumor Imaging Categorical Course. Only Lung Cancer talks are listed. No book comes with this purchase. Participants will learn how to screen for lung cancer, assuring high-quality care. They will also discover ways to reduce healthcare inequities. This course covers screening, therapies, problems, and the future of lung cancer screening.
Goal Audience:
This activity is for lung cancer screening-focused radiologists and trainees.
Goal of Lung Cancer 2022:
- By the end of this article, readers will understand how imaging and staging affect lung cancer therapy response.
- Learn about lung cancer staging and imaging hazards.
- Let’s examine lung cancer treatment imaging.
- Report on current screening and radiologic reporting programs.
- Explain primary and secondary lung neoplasm therapy options.
Module 1: Lung Cancer Screening, Missed Cases and Staging
- Efren Flores has nothing to disclose.
- Suzanne Byrne has nothing to disclose.
- Lucy Modahl has nothing to disclose.
- Dexter Mendoza has nothing to disclose.
- Alejandra Cardona has nothing to disclose.
- Mark H. Hammer has nothing to disclose.
- Francine L. Jacobson has nothing to disclose.
- Jo-Anne O. Shepard has nothing to disclose.
- John M. Archer has nothing to disclose.
Module 2: Lung Cancer Imaging Interventions and Advancements
- Florian Fintelmann has nothing to disclose.
- Saurabh Agarwal has nothing to disclose.
- Subba Digumarthy receives an honorarium as an instructor at a workshop for Siemens Medical Solutions.
- Rydhwana Hossain has nothing to disclose.
- Mark C. Murphey has nothing to disclose.
- Maria M. Wrobel has nothing to disclose.
- Alexis M. Cahalane has nothing to disclose.
- John M. Archer has nothing to disclose.
- Amanda Marrero has nothing to disclose.
- Allison Herring has nothing to disclose.
- Charles White is on Riverain Medical’s Advisory Board and the recipient of financial compensation.
Reviews
There are no reviews yet.